Anti-hypoxia nanosized drug delivery systems improving cancer therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tumor microenvironment: sanctuary of the devil10.1016/j.canlet.2015.07.039 ↗
2. Influence of tumour micro-environment heterogeneity on therapeutic response10.1038/nature12626 ↗
3. Imaging the tumor microenvironment10.1007/978-3-319-67577-0_15 ↗
4. The biology and function of fibroblasts in cancer10.1038/nrc.2016.73 ↗
5. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
6. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis10.1016/j.ccr.2014.03.021 ↗
7. Tumor microenvironment and therapeutic response10.1016/j.canlet.2016.01.043 ↗
8. Cancer prevention and therapy through the modulation of the tumor microenvironment10.1016/j.semcancer.2015.02.007 ↗
9. The updated landscape of tumor microenvironment and drug repurposing10.1038/s41392-020-00280-x ↗
10. The future of cancer immunotherapy: microenvironment-targeting combinations10.1038/s41422-020-0337-2 ↗
11. Hypoxia--a key regulatory factor in tumour growth10.1038/nrc704 ↗
12. Oxygen regulation of gene expression: a study in opposites10.1006/mgme.2000.3074 ↗
13. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics10.1038/onc.2009.441 ↗
14. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment10.2147/IJN.S140462 ↗
15. Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development10.1016/j.apsb.2020.01.004 ↗
16. Hyperbaric oxygen therapy and cancer--a review10.1007/s11523-012-0233-x ↗
17. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia10.1158/2326-6066.CIR-16-0103 ↗
18. Targeting hypoxia in cancer therapy10.1038/nrc3064 ↗
19. Polymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier10.1038/s41598-020-68190-0 ↗
20. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury10.1371/journal.pbio.0030174 ↗
21. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
22. Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia10.1016/j.jconrel.2020.05.029 ↗
23. Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia10.1016/j.biomaterials.2019.119578 ↗
24. Retooling cancer nanotherapeutics’ entry into tumors to alleviate tumoral hypoxia10.1002/smll.202003000 ↗
25. Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy10.1016/j.jconrel.2019.12.028 ↗
26. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance10.3389/fmolb.2020.00193 ↗
27. Advanced nanotechnology for hypoxia-associated antitumor therapy10.1039/C9NR09071A ↗
28. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy10.1016/S0093-7754(01)90210-6 ↗
29. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers
30. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy10.1038/s42255-019-0045-8 ↗
31. Molecular landmarks of tumor hypoxia across cancer types10.1038/s41588-018-0318-2 ↗
32. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
33. Tumor hypoxia and malignant progression10.1016/S0076-6879(04)81023-1 ↗
34. Zone-specific remodeling of tumor blood vessels affects tumor growth10.1002/cncr.23024 ↗
35. Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors - a review
36. Spectral imaging facilitates visualization and measurements of unstable and abnormal microvascular oxygen transport in tumors10.1117/1.2837439 ↗
37. 2019 Nobel Prize awarded for work on oxygen regulation10.1016/S0140-6736(19)32332-3 ↗
38. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 Sensing10.1126/science.1059817 ↗
39. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation10.1126/science.1059796 ↗
40. The ever-expanding role of HIF in tumour and stromal biology10.1038/ncb3330 ↗
41. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 110.1074/jbc.271.51.32529 ↗
42. The Warburg effect: how does it benefit cancer cells?10.1016/j.tibs.2015.12.001 ↗
43. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer10.1016/S0360-3016(01)01630-3 ↗
44. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation10.1128/MCB.21.4.1297-1310.2001 ↗
45. regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors
46. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis10.1038/sj.onc.1203814 ↗
47. A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: roles of nuclear factor-κB and Bcl-210.1046/j.1471-4159.2000.0750683.x ↗
48. Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis10.1038/s41467-019-12412-1 ↗
49. Hypoxia and the extracellular matrix: drivers of tumour metastasis10.1038/nrc3726 ↗
50. Hypoxia triggers the intravasation of clustered circulating tumor cells10.1016/j.celrep.2020.108105 ↗
51. Regulation of angiogenesis by hypoxia: role of the HIF system10.1038/nm0603-677 ↗
52. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors10.1161/01.RES.0000093984.48643.D7 ↗
53. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells10.1016/S0006-291X(02)02707-9 ↗
54. Role of hypoxia in cancer therapy by regulating the tumor microenvironment10.1186/s12943-019-1089-9 ↗
55. Impact of tumor hypoxia and anemia on radiation therapy outcomes10.1634/theoncologist.7-6-492 ↗
56. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy10.1186/1471-2407-5-42 ↗
57. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?10.1007/s00066-003-1150-9 ↗
58. of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
59. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial10.1200/JCO.2005.02.7474 ↗
60. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients10.1007/s12094-020-02332-8 ↗
61. Treatment reisitance of solid tumors10.1385/MO:18:4:243 ↗
62. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance10.1038/bjc.1991.405 ↗
63. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer10.3892/or.2015.4536 ↗
64. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer
65. HIF-1alpha inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein
66. Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy10.1016/j.ccell.2015.03.014 ↗
67. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation10.1084/jem.20131916 ↗
68. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells10.1093/intimm/dxh194 ↗
69. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift10.1038/s41388-019-0782-x ↗
70. Hypoxia and tumor-associated macrophages: a deadly alliance in support of tumor progression10.4161/onci.27561 ↗
71. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues10.1182/blood-2004-03-1109 ↗
72. Immunological mechanisms of the antitumor effects of supplemental oxygenation
73. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours10.1007/s12032-016-0814-0 ↗
74. Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy
75. Hyperbaric oxygen regulates tumor microenvironment and boosts commercialized nanomedicine delivery for potent eradication of cancer stem-like cells10.1016/j.nantod.2021.101248 ↗
76. Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy
77. Hyperbaric oxygen and radiotherapy10.1007/s00066-005-1277-y ↗
78. Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review10.1016/j.radonc.2004.04.005 ↗
79. An experimental study of the use of hyperbaric oxygen to reduce the side effects of radiation treatment for malignant disease10.1016/j.ijom.2007.03.003 ↗
80. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers?10.1016/0360-3016(86)90167-7 ↗
81. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma
82. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model10.1067/mtc.2003.90 ↗
83. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors10.1016/j.canlet.2004.02.012 ↗
84. Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction, Eur10.1016/S1010-7940(00)00592-3 ↗
85. Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia10.1007/s00066-015-0867-6 ↗
86. Multiple etiologies of tumor hypoxia require multifaceted solutions10.1158/1078-0432.CCR-06-2629 ↗
87. Hypoxia and radiation therapy: past history, ongoing research, and future promise10.2174/156652409788167087 ↗
88. Anemia, tumor hypoxemia, and the cancer patient10.1016/j.ijrobp.2005.04.049 ↗
89. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial10.1016/S0140-6736(03)14567-9 ↗
90. Artificial O2 carriers: status in 200510.2174/138161205774913354 ↗
91. Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice10.1111/j.1525-1594.2011.01418.x ↗
92. Oxygen therapeutics - Pursuit of an alternative to the donor red blood cell10.5858/2007-131-734-OTPOAA ↗
93. Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas10.1371/journal.pone.0184250 ↗
94. Effects of hyperbaric-oxygen and a perfluorooctylbromide emulsion on the radiation responses of tumors and normal-tissues in rodents10.1016/0360-3016(92)90986-R ↗
95. A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors10.1016/0360-3016(90)90551-T ↗
96. Phase 3 enrich (RT-016) comparative study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer
97. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases
98. Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer10.1016/j.ijrobp.2008.06.880 ↗
99. Fractals and cancer
100. Barriers to drug-delivery in solid tumors10.1038/scientificamerican0794-58 ↗